Immutep Receives Australian R&D Tax Incentive
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immutep (ASX: IMM; NASDAQ: IMMP) announced it has secured a cash rebate of A$986,286 (~US$659,303) from the Australian Federal Government's R&D tax incentive program for eligible R&D activities in the 2021 fiscal year, particularly for its TACTI-002 clinical study involving eftilagimod alpha (efti). This follows a previous EU tax incentive of €1,804,341 (~US$1,862,143). The funds will support ongoing clinical trials, with cash flow expected to last into the first half of 2024.
Positive
- Secured A$986,286 (~US$659,303) cash rebate from Australian R&D tax incentive.
- Received €1,804,341 (~US$1,862,143) French tax incentive for eligible R&D expenses.
- Non-dilutive funding will support ongoing clinical trials for eftilagimod alpha.
Negative
- None.
Details
News Market Reaction – IMMP
The recorded move for IMMP in the trading session of this news was -3.93%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Media Release (Code: ASX: IMM; NASDAQ: IMMP)
SYDNEY, AUSTRALIA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A
This follows approval from AusIndustry of Immutep’s application for an Advance/Overseas Finding. Due to the Advance Finding, both Immutep’s Australian and overseas research and development activities related to the TACTI-002 Australian sites are eligible for the R&D Tax Incentive.
As previously announced, in September 2022, Immutep also received the French CIR tax incentive of
Immutep will apply the non-dilutive funding towards furthering its current active clinical trial programs for its lead product candidate, efti. The expected cash reach of the Company extends into 1st half of calendar year 2024.
About Immutep
Immutep is a clinical stage biotechnology company leading the development of LAG-3 related immunotherapy products for the treatment of cancer and autoimmune disease. The Company is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.
Immutep’s lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer in multiple clinical trials. The Company is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 product candidates, including antibodies for immune response modulation, are licensed to and being developed by Immutep’s large pharmaceutical partners.
Further information can be found on the Company’s website www.immutep.com or by contacting:
Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com
U.S. Media:
Tim McCarthy, LifeSci Advisors
+1 (917) 679 9282; tim@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.